Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/13/21
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 04/18/23
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 07/26/23
End: 03/31/28
Due: 03/31/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | NCT04712864 | Legend Biotech USA Inc | user2@example.com | None | 2021-09-13 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | NCT05539430 | Legend Biotech USA Inc | user2@example.com | None | 2023-04-18 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | NCT05680922 | Legend Biotech USA Inc | user2@example.com | None | 2023-07-26 | 2028-03-31 | 2029-03-31 | - | - | 2025-07-14 |